Jim Cramer's Take on Vertex: Tackling Opioid Addiction with New Drug in Pipeline
Portfolio Pulse from Vandana Singh
CNBC's Jim Cramer has highlighted Vertex Pharmaceuticals' development of a non-opioid drug, VX-548, to treat acute pain. The drug is in the late stages of development and is expected to disrupt the pain management market. Cramer's Charitable Trust has a vested interest in Eli Lilly And Co, primarily due to its drug, Mounjaro, which is expected to expand its approved uses to include obesity treatment by the end of the year.
October 09, 2023 | 6:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's drug, Mounjaro, is expected to expand its approved uses to include obesity treatment by the end of the year.
The expansion of Mounjaro's approved uses could increase Eli Lilly's revenue and market share, potentially leading to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Vertex Pharmaceuticals is developing a non-opioid drug, VX-548, which is expected to disrupt the pain management market.
The development of a non-opioid drug for acute pain treatment could significantly increase Vertex's market share and revenue, leading to a potential increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100